HRP20040782A2 - Substituted 3-phenyl-5-akoxy-1,3,4-oxadiazol-2-ones, the production therof and their use in medicaments - Google Patents

Substituted 3-phenyl-5-akoxy-1,3,4-oxadiazol-2-ones, the production therof and their use in medicaments Download PDF

Info

Publication number
HRP20040782A2
HRP20040782A2 HR20040782A HRP20040782A HRP20040782A2 HR P20040782 A2 HRP20040782 A2 HR P20040782A2 HR 20040782 A HR20040782 A HR 20040782A HR P20040782 A HRP20040782 A HR P20040782A HR P20040782 A2 HRP20040782 A2 HR P20040782A2
Authority
HR
Croatia
Prior art keywords
formula
compounds
alkyl
phenyl
oxadiazol
Prior art date
Application number
HR20040782A
Other languages
English (en)
Croatian (hr)
Inventor
Schoenafinger Karl
Petry Stefan
M�ller G�nter
Bauer Armin
Hubert
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of HRP20040782A2 publication Critical patent/HRP20040782A2/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/1131,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
HR20040782A 2002-02-28 2003-02-14 Substituted 3-phenyl-5-akoxy-1,3,4-oxadiazol-2-ones, the production therof and their use in medicaments HRP20040782A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10208987A DE10208987A1 (de) 2002-02-28 2002-02-28 Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxidiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
PCT/EP2003/001484 WO2003072555A1 (de) 2002-02-28 2003-02-14 Substituierte 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-one sowie ihre herstellung und verwendung in arzneistoffen

Publications (1)

Publication Number Publication Date
HRP20040782A2 true HRP20040782A2 (en) 2005-02-28

Family

ID=27740558

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040782A HRP20040782A2 (en) 2002-02-28 2003-02-14 Substituted 3-phenyl-5-akoxy-1,3,4-oxadiazol-2-ones, the production therof and their use in medicaments

Country Status (22)

Country Link
EP (1) EP1480960B1 (enExample)
JP (1) JP4486363B2 (enExample)
KR (1) KR20040095240A (enExample)
CN (1) CN1639137A (enExample)
AR (1) AR038701A1 (enExample)
AT (1) ATE557012T1 (enExample)
AU (1) AU2003226977A1 (enExample)
BR (1) BR0307921A (enExample)
CA (1) CA2477031A1 (enExample)
CO (1) CO5611146A2 (enExample)
DE (1) DE10208987A1 (enExample)
HR (1) HRP20040782A2 (enExample)
HU (1) HUP0402671A3 (enExample)
IL (1) IL163683A0 (enExample)
MA (1) MA27172A1 (enExample)
MX (1) MXPA04007960A (enExample)
NO (1) NO20044090L (enExample)
PE (1) PE20030928A1 (enExample)
PL (1) PL370423A1 (enExample)
RU (1) RU2004128933A (enExample)
TW (1) TW200400951A (enExample)
WO (1) WO2003072555A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074822B2 (en) 2004-02-23 2006-07-11 Solvay Pharmaceuticals Gmbh Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them
WO2006045799A2 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
CA2710743A1 (en) * 2007-12-27 2009-07-09 Bial-Portela & Ca., S.A. 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use
WO2010074587A2 (en) 2008-12-23 2010-07-01 Bial - Portela & Ca., S.A. 5-o-substituted 3-n-aryl-1,3,4-oxadiazolones for medical use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19942354A1 (de) * 1999-09-04 2001-03-08 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneimitteln
SK12752002A3 (sk) * 2000-03-07 2003-04-01 Aventis Pharma Deutschland Gmbh Substituované 3-fenyl-5-alkoxy-1,3,4-oxdiazol-2-óny, spôsob ich prípravy a ich použitie ako liečivo na inhibovanie hormónsenzitívnej lipázy

Also Published As

Publication number Publication date
HUP0402671A3 (en) 2006-07-28
JP2005519085A (ja) 2005-06-30
AU2003226977A1 (en) 2003-09-09
CA2477031A1 (en) 2003-09-04
PL370423A1 (en) 2005-05-30
EP1480960A1 (de) 2004-12-01
AR038701A1 (es) 2005-01-26
NO20044090L (no) 2004-11-04
TW200400951A (en) 2004-01-16
JP4486363B2 (ja) 2010-06-23
EP1480960B1 (de) 2012-05-09
CO5611146A2 (es) 2006-02-28
KR20040095240A (ko) 2004-11-12
IL163683A0 (en) 2005-12-18
MA27172A1 (fr) 2005-01-03
PE20030928A1 (es) 2003-12-17
DE10208987A1 (de) 2003-09-11
MXPA04007960A (es) 2004-11-26
HUP0402671A2 (hu) 2005-04-28
ATE557012T1 (de) 2012-05-15
WO2003072555A1 (de) 2003-09-04
RU2004128933A (ru) 2005-04-20
BR0307921A (pt) 2004-12-21
CN1639137A (zh) 2005-07-13

Similar Documents

Publication Publication Date Title
US7795283B2 (en) Oxadiazole derivative as DGAT inhibitors
EP1988091B1 (en) Tricyclic compounds
EP1635824B1 (en) 5-membered heterocycle-based p-38 inhibitors
EP2260028B1 (en) Selective androgen receptor modulators
US8268872B2 (en) Selective androgen receptor modulators
EP1813606A1 (en) Amide compound
US20080305169A1 (en) Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
HUT77129A (hu) 2,3,4,5-Tetrahidro-1,4-benzotiazepin-1,1-dioxid-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
EP2178872A1 (en) Paliperidone derivatives
SK12752002A3 (sk) Substituované 3-fenyl-5-alkoxy-1,3,4-oxdiazol-2-óny, spôsob ich prípravy a ich použitie ako liečivo na inhibovanie hormónsenzitívnej lipázy
US6596742B1 (en) Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use in medicaments
US20040127426A1 (en) Peptidic compounds as cysteine protease inhibitors
HRP20040782A2 (en) Substituted 3-phenyl-5-akoxy-1,3,4-oxadiazol-2-ones, the production therof and their use in medicaments
KR20040101250A (ko) 췌장 리파제를 억제하는 약제를 제조하기 위한 치환된3-페닐-5-알콕시-1,3,4-옥스디아졸-2-온의 용도
TW202239756A (zh) 作為組蛋白去乙醯酶6抑制劑之1,3,4-㗁二唑硫羰基化合物及包含該等化合物之醫藥組合物
US6900233B2 (en) Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof
EP2546255A1 (en) Benzazepine compound
US20030236288A1 (en) Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
CA2770405A1 (en) Sulfone derivative
MXPA05011102A (es) Derivados de 1-([1,4]dioxan-2-il)-benzotiazol como ligandos de receptor de adenosina.
BRPI0619282B1 (pt) Sal, e composição farmacêutica
CA3131388A1 (en) Pyrazolopyridine compounds for ire1 inhibition
CN101115731A (zh) 作为dgat抑制剂的二唑衍生物
RU2065855C1 (ru) Производные 3-(2-замещенный фенил)-2-(замещенный имино)-тиазолидинов или их фармацевтически приемлемые соли и фармацевтическая композиция, обладающая антиангинальным и/или антиневралгическим эффектом
HK1107091A (en) Amide compound

Legal Events

Date Code Title Description
ODRP Renewal fee for the maintenance of a patent

Payment date: 20050118

Year of fee payment: 3

A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn